Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4238504 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP).

The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Should I Continue Taking My Acid Reflux Medication? Development and Pilot Testing of a Patient Decision Aid

NCT02558049

Proton Pump Inhibitors Gastroesophageal Reflux Disease

COMPLETED NA

Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease

NCT00829738

Gastroesophageal Reflux Disease

COMPLETED

Effect of Daily Use Proton Pump Inhibitors for One Month on Kidney Function

NCT03910647

Proton Pump Inhibitor Allergy

UNKNOWN PHASE2

A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes

NCT00681005

GERD

COMPLETED NA

A Study of Breath Testing for Small Intestinal Bacterial Overgrowth

NCT05976165

Gastroesophageal Reflux Regurgitation Heartburn

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Previous observational studies have found an association between proton pump inhibitors (PPIs), a class of medications used to treat gastric conditions, and the risk of community acquired pneumonia. These studies, however, had important limitations including confounding by indication and protopathic bias. The purpose of this study is to determine whether PPIs increase the risk of hospitalization for community-acquired pneumonia (HCAP). To overcome the limitations of previous studies that examined this issue, this study will be conducted in a cohort of new users of non-steroidal anti-inflammatory drugs (NSAIDs), in whom PPIs are often prescribed prophylactically to prevent dyspepsia and other gastric side effects.

The investigators will use a common-protocol approach to conduct retrospective cohort studies using administrative health care data from eight jurisdictions (the Canadian provinces of Alberta, Saskatchewan, Manitoba, Ontario, Quebec, and Nova Scotia, as well as the United States (US) MarketScan, and the United Kingdom (UK) General Practice Research Database \[GPRD\]). Briefly, the Canadian databases include population-level data on physician billing, diagnoses and procedures from hospital discharge abstracts, and dispensations for prescription drugs. Alberta, Nova Scotia, Ontario, and Quebec data will be restricted to patients aged 65 years and older as prescription data are not available for younger patients. For Quebec, a 10% random sample of eligible patients will be used. The GPRD is a clinical database that is representative of the UK population and contains the records for patients seen at over 680 general practitioner practices in the UK. US MarketScan includes individuals and their dependents covered by large U.S. employer health insurance plans, and government and public organizations. As Medicare eligibility begins for those above the age of 65, the US MarketScan data will be restricted to patients aged 40 to 65 years in order to ensure complete data capture.

In each jurisdiction, the investigators will assemble a source population that includes all patients with a prescription for an oral NSAID (WHO Anatomical Therapeutic Chemical (ATC) Code M01A). From this source population, a study cohort will be created including all patients who received a prescription for an oral NSAID of ≥ 30 days duration, as patients receiving short duration prescriptions are unlikely to be prescribed a PPI for prophylactic reasons. The date of prescription (for the GPRD) or dispensation (for all other sites) of the oral NSAID will define the date of study cohort entry.

Patients will be followed from the date of study cohort entry until an event (defined below) or censoring due to death, departure from the database, end of follow-up (180 days), or the end of the study period (September 30, 2011 or the last date of data availability at that site), whichever occurs first. Patients will be permitted to enter the cohort multiple times provided that all inclusion criteria are met.

The investigators will create three mutually exclusive exposure categories: 1) PPI users, 2) H2RA users, and 3) unexposed patients. The investigators will use an analysis analogous to an intention-to-treat approach. Exposure to PPIs will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole) on the same day as their cohort entry defining prescription for an NSAID. Exposure to H2RAs will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as their cohort entry defining prescription for an NSAID. Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as their cohort entry defining prescription for an NSAID. The primary outcome will be defined as incident HCAP during the 6 months following initiation of NSAID therapy.

Multiple logistic regression will be used to estimate site-specific adjusted odds ratios (aORs) and corresponding 95% confidence intervals (CIs) for the association of incident HCAP at 6 months and PPI exposure. This is considered the primary analysis. Several sensitivity analyses will be performed to assess the robustness of study results. Such analyses include: restricting analyses to a single, random, observation per patient; excluding patients who received a prescription for a PPI, H2RA, or NSAID in the 12 months before cohort entry; and excluding crossovers between PPI and H2RAs. High dimensional propensity scores will be estimated for all patients in the cohort using logistic regression. Finally, all site-specific estimates will be meta-analyzed using fixed models with inverse variance weighting. The amount of between-site heterogeneity will be estimated using the I-squared statistic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux Disease (GERD) Community-acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Users of PPIs

Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.

esomeprazole

Intervention Type DRUG

Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.

omeprazole

Intervention Type DRUG

Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.

pantoprazole

Intervention Type DRUG

Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.

lansoprazole

Intervention Type DRUG

Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.

rabeprazole

Intervention Type DRUG

Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.

Users of H2RAs

Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.

cimetidine

Intervention Type DRUG

Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.

ranitidine

Intervention Type DRUG

Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.

famotidine

Intervention Type DRUG

Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.

nizatidine

Intervention Type DRUG

Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.

niperotidine

Intervention Type DRUG

Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.

roxatidine

Intervention Type DRUG

Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.

ranitidine bismuth citrate

Intervention Type DRUG

Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.

lafutidine

Intervention Type DRUG

Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.

cimetidine combinations

Intervention Type DRUG

Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.

famotidine combinations

Intervention Type DRUG

Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.

Unexposed group (Reference)

Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

esomeprazole

Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

omeprazole

Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

pantoprazole

Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

lansoprazole

Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

rabeprazole

Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

cimetidine

Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

ranitidine

Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

famotidine

Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.

Intervention Type DRUG

nizatidine

Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

niperotidine

Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

roxatidine

Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

ranitidine bismuth citrate

Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

lafutidine

Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

cimetidine combinations

Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

famotidine combinations

Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Proton pump inhibitor Proton pump inhibitor Proton pump inhibitor Proton pump inhibitor Proton pump inhibitor histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist histamine-2 receptor antagonist

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a first oral NSAID prescription
* Patients at least 40 years of age (except Alberta, Ontario, and Nova Scotia, where patients will be at least 66 years of age)
* Patients with at least 1 year of history in the database.

Exclusion Criteria

* Patients aged \< 40 years at cohort entry (or \< 66 in Alberta, Ontario, and Nova Scotia)
* Received a prescription for a PPI, a H2RA, or a NSAID (any route of administration) in the 6 months prior to cohort entry
* Had an HCAP (ICD-9-CM code (in any field): 480.x-487.x; ICD-10-CA code: J10.0 - J18.9) or an extended emergency room visit for community-acquired pneumonia in the year prior to cohort entry (where available)
* Hospitalized at the time of cohort entry
* Received a prescription for medications used for the treatment of tuberculosis (ATC Code J04A) (where available)
* Had a history of cancer (other than non-melanoma skin cancer) in the year prior to cohort entry
* Hospitalized \>3 days within the 30 days before cohort entry
* Had \<1 year of continuous observation time in the database prior to cohort entry

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No